LeMaitre Vascular (LMAT) vs PROCEPT BioRobotics (PRCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LeMaitre Vascular (LMAT) has outperformed PROCEPT BioRobotics (PRCT) over the past year, losing 16.3% versus a loss of 17.3%. Over five years, LMAT leads with a +51.0% price change compared with -30.6% for PRCT. LeMaitre Vascular is the larger company by market cap ($1.68 billion vs $1.42 billion), about 1.2 times the size, while PROCEPT BioRobotics is growing revenue faster (+37.2% vs +13.5%).
LeMaitre Vascular pays a dividend yielding 1.29%, while PROCEPT BioRobotics does not currently pay one. LeMaitre Vascular converts more of its revenue into profit, with a net margin of 23.1% versus -31.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMAT | PRCT |
|---|---|---|
| Share price | $73.61 | $24.70 |
| Market cap | $1.68B | $1.42B |
| 1-day change | -1.67% | -4.08% |
| YTD return | -9.24% | -21.49% |
| 1-year return | -16.29% | -17.28% |
| 5-year return | +50.96% | -30.64% |
| P/E ratio (TTM) | 26.77 | — |
| Forward P/E | 23.37 | — |
| EPS (TTM) | $2.75 | $-2.02 |
| Dividend yield | 1.29% | 0.00% |
| Annual dividend | $0.95 | $0.00 |
| Revenue (latest FY) | $249.60M | $308.05M |
| Revenue growth (YoY) | +13.53% | +37.22% |
| Net income (latest FY) | $57.73M | $-95.57M |
| Gross margin | 71.53% | 63.70% |
| Operating margin | 27.21% | -33.71% |
| Net margin | 23.13% | -31.02% |
| 52-week high | $118.01 | $38.11 |
| 52-week low | $73.44 | $16.67 |
| Distance from 52-week high | -37.62% | -35.19% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +34.89% | -7.89% |
| Average volume | 277.19K | 1.31M |
| Shares outstanding | 22.88M | 57.54M |
| Employees | 646 | 888 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.29% vs 0.00%).
- LeMaitre Vascular is more profitable, keeping 23.1 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
- PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs +13.53%).
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
LMAT vs PRCT FAQ
Which is bigger, LeMaitre Vascular or PROCEPT BioRobotics?
LeMaitre Vascular (LMAT) is larger, with a market capitalization of $1.68B compared with $1.42B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, LMAT or PRCT?
LMAT returned -16.29% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, LeMaitre Vascular or PROCEPT BioRobotics?
LeMaitre Vascular pays a dividend yielding 1.29%, while PROCEPT BioRobotics does not currently pay a regular dividend.
Are LeMaitre Vascular and PROCEPT BioRobotics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.